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Abstract
Introduction Experimental and clinical data show that the oral
bisphosphonate clodronate (Bonefos®) can inhibit tumor-
induced osteoclastic bone resorption. This randomized, double-
blind, placebo-controlled, multicenter trial was designed to
determine if the addition of oral clodronate to standard treatment
for primary operable breast cancer could reduce the
subsequent occurrence of bone metastases and thereby
improve overall survival.
Methods 1,069 patients with primary operable stage I-III breast
cancer were randomized to receive oral clodronate (1,600 mg/
day) or placebo for 2 years, in conjunction with standard
treatment for primary breast cancer including surgery,
radiotherapy, adjuvant chemotherapy, and/or tamoxifen. All
patients were assessed for bone metastases at two and five
years and additionally when clinically indicated. Survival status
was determined as of the close of the study on 30 June 2000
with a median follow up of 5.6 years. The treatment arms were
compared using the unstratified log-rank test. Hazard ratios
(HRs) with 95% confidence intervals were calculated.
Results Oral clodronate significantly reduced the risk of bone
metastases in all patients over the 5 year study period (51
patients versus 73 patients with placebo; HR = 0.692, P =
0.043); the difference was also statistically significant over the
2 year medication period (19 patients versus 35 patients with
placebo; HR = 0.546, P = 0.031). These differences were most
pronounced in patients with stage II/III disease (39 patients
versus 64 patients with placebo, HR = 0.592, P = 0.009 over 5
years; 16 patients versus 32 patients with placebo, HR= 0.496,
P = 0.020 over 2 years). Survival data also favoured the
clodronate arm (HR for all patients = 0.768, P = 0.048; HR for
stage II/III disease = 0.743, P = 0.041), although this was not
significant due to multiple analyses. Oral clodronate was well
tolerated, with mild-to-moderate diarrhoea being the most
frequently reported adverse event.
Conclusion These results confirm that oral clodronate will
significantly improve the 5 year bone relapse free survival when
used as a supplementary adjuvant treatment for patients
receiving standard treatment for primary operable breast cancer.
Introduction
Adjuvant therapy of primary operable breast cancer using
endocrine or chemotherapy represents a major advance in the
treatment of this disease and has resulted in a significant
improvement in relapse free and overall survival [1,2]. Bone is
the most common distant site of recurrence for patients with
breast cancer [3] and appears to be the site of metastases
that gains least benefit from adjuvant chemotherapy [4].
CI = confidence interval; CT = computed tomography; HR = hazard ratio; MRI = magnetic resonance imaging.
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Experimentally, anti-osteolytic agents including bisphospho-
nates have been shown to prevent the development of bone
metastases in various animal models [5-9]. Bisphosphonates
exert their anti-osteolytic effects by inhibiting osteoclast activ-
ity, and this mechanism is postulated to be the mechanism for
prevention of experimental metastases [10,11]. Several pla-
cebo-controlled trials have reported that oral clodronate, oral
ibandronate or intravenous pamidronate will reduce the skele-
tal complications in patients with metastatic breast cancer
[12-15]. Oral clodronate has also been shown to reduce the
incidence of bone metastases in women with advanced breast
cancer [16] and in patients with primary breast cancer [17].
This randomized, double-blind, placebo-controlled study was
designed to determine if oral clodronate 1,600 mg daily for 2
years in conjunction with standard adjuvant therapy could
reduce the incidence of bone metastases in patients with pri-
mary, stageI-III breast cancer. Earlier analyses of this study
were previously published [18,19]. We now report the final
analyses of these data.
Materials and methods
Patients
This study population has been described previously. Briefly,
all patients (N = 1,069) had histologically or cytologically con-
firmed primary operable breast cancer with no evidence of
metastasis, and were recruited between 1989 and 1995. Pri-
mary treatment consisted of surgery and/or radiotherapy with
or without systemic endocrine therapy and/or chemotherapy.
Patients were excluded if they had significant renal, hepatic, or
non-malignant bone disease; other exclusion criteria included
a history of malignant disease or prior bisphosphonate use. All
patients were required to be both psychologically and physi-
cally suitable for 2 years of treatment with oral clodronate or
placebo. In accordance with the Declarations of Helsinki, all
patients provided written informed consent prior to study par-
ticipation.
Study design
This randomized, double-blind, placebo-controlled, multina-
tional, multicenter study designed to determine whether oral
clodronate 1,600 mg daily for 2 years could reduce the occur-
rence of bone metastases over the 5 year study period. Eligi-
ble patients were stratified prior to randomization by center
and by use of chemotherapy for pre-menopausal women. All
patients were assessed for bone metastases at 2 years and 5
years and otherwise when clinically indicated. Clinical labora-
tory tests were repeated every 3 months during the first year
of the study, and every 6 months during years 2 through 5.
Patients were followed for survival until the study was formally
closed on 30 June 2000 (median follow-up: 5.6 years; range
5 years to 10 years 6 months).
Figure 1
Incidence of bone metastases in all patients. HR, hazard ratio.
Table 1
Baseline demographics and clinical characteristics
Characteristic Clodronate  (n = 
530)
Placebo  (n = 539)
Mean age ± SD 
(years)
52.8 ± 10.6 52.7 ± 10.5
Mean BMI ± SD (kg/
m2)
25.8 ± 4.5 25.8 ± 4.8
Menopausal status 
(n)
Premenopausal 265 (50%) 265 (49%)
Postmenopausal 265 (50%) 274 (51%)
Axillary lymph node 
involvement (n)
196 (37%) 202 (38%)
Tumor stage (n)
I 137 (26%) 143 (26%)
II 304 (57%) 305 (57%)
III 48 (9%) 52 (10%)
Unclassifiable 40 (8%) 39 (7%)
Missing 1 (0.2%) 0 (0%)
Hormone receptor 
status (n)
Oestrogen 
receptor-
positive
245 (46%) 240 (45%)
Oestrogen 
receptor-
negative
136 (26%) 136 (25%)
Oestrogen 
receptor-
unknown
149 (28%) 163 (30%)
Progesterone 
receptor-
positive
112 (21%) 116 (22%)
Progesterone 
receptor-
negative
79 (15%) 75 (14%)
Progesterone 
receptor-
unknown
339 (64%) 348 (65%)
BMI, body mass index; SD, standard deviation.
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Each new patient was registered and randomized at each par-
ticipating center by means of numerically ordered and coded
packages containing either oral clodronate or placebo accord-
ing to a centralized blinded code. Prior to randomization, the
initial screening process included obtaining a clinical history,
conducting a physical examination, assessing hematological,
renal and hepatic function, determining urinary calcium,
hydroxyproline and creatinine levels, and taking skeletal radio-
graphs and bone scintigraphy. Other clinical investigations
included computed tomography (CT) scanning and magnetic
resonance imaging (MRI), if indicated. Radiological assess-
ments for the detection of bone metastases were repeated at
the end of the 2 year treatment period and again at the end of
the 5 year study period (or at any other time, if clinically indi-
cated).
At relapse, the study blind was maintained and patients
received appropriate local or systemic therapies according to
the treatment protocols of the individual study center. Study
medication (oral clodronate or placebo) was discontinued if
bone metastases occurred, and bisphosphonate therapy
could be administered for treatment of bone metastases at the
investigator's discretion.
Study endpoints and evaluation
The primary efficacy endpoint was time to first bone metas-
tases over the 5 year study period, and the secondary end-
points included overall survival and the occurrence of non-
skeletal relapses. Bone metastases were diagnosed by iso-
topic bone scan, skeletal X-rays and CT or MRI if required. The
final diagnosis of bone metastases and subsequent audits of
the data were always performed blinded to the patient's study
medication. The date of first bone relapse was determined as
the date of the first test abnormality in patients subsequently
confirmed as bone metastatic relapse. Vertebral collapse
required confirmation of bone metastasis with MRI or CT. Non-
osseous metastases were categorized as either soft-tissue
metastases (for example, skin, lymph node, or other breast) or
as visceral metastases (lung, pleura, liver, or central nervous
system). The date of the first positive diagnostic test indicated
the event date.
The incidence of adverse events and laboratory abnormalities
were assessed every 3 months during the first year of treat-
ment and every 6 months during years 2 to 5.
Statistical methods
The target sample size of 1,000 patients was calculated to
provide 95% power to detect a 25% reduction in bone metas-
tases over 5 years. Efficacy endpoints were analyzed by
Table 2
Incidence of bone metastases and mortality
Clodronate (n = 530) Placebo (n = 539) Hazard ratio (95% CI) P value
Bone metastases (all patients)
2 years 19 (3.6%) 35 (6.5%) 0.546 (0.312, 0.954) 0.031
5 years 51 (9.6%) 73 (13.5%) 0.692 (0.484, 0.990) 0.043
Bone metastases (stage II/III)
n 352 357
2 years 16 (3.0%) 32 (6.0%) 0.496 (0.272, 0.975) 0.020
5 years 39 (7.4%) 64 (11.8%) 0.592 (0.398, 0.882) 0.009
Visceral metastases
2 years 39 (7.3%) 47 (8.7%) 0.84 (0.55,1.29) 0.428
5 years 79 (14.9%) 94 (17.4%) 0.84 (0.62,1.13) 0.241
Visceral metastases (stage II/III)
n 352 357
2 years 34 (9.7%) 42 (11.8%) 0.81 (0.52,1.28) 0.372
5 years 64 (18.2%) 81 (22.7%) 0.77 (0.56,1.07) 0.120
Deaths during follow-up (median follow-up, 5.6 years)
All patients 98 (18.5%) 129 (23.9%) 0.768 (0.591, 0.999) 0.048
Stage II/III 82 (23.3%) 110 (30.8%) 0.743 (0.558, 0.989) 0.041
CI, confidence interval.
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unstratified log-rank statistic; hazard ratios (HRs) with 95%
confidence intervals (CIs) were calculated using a Cox regres-
sion model with treatment as the only effect. As interim analy-
ses using the O'Brien Flemming stopping rules had been
conducted, to maintain an overall alpha level of 0.05, the final
analyses presented herein are considered statistically signifi-
cant if P d 0.048.
Comparability of treatment groups at baseline were compared
using a multi-way ANOVA for continuous variables and logistic
regression for categorical variables.
Primary analyses were conducted on the intent-to-treat popu-
lation (1,069 patients). Analyses are also presented for subset
of patients diagnosed with stage II/III disease as they are rec-
ognized to be at higher risk for metastases.
To address the issue regarding the possible compromise of
treatment for patients with bone metastases by the previous
use of adjuvant clodronate, we have examined the occurrence
of metastatic bone events and mortality in the patients who
developed bone metastases. These events included the
requirement for osseous radiation therapy, the occurrences of
metastatic fractures, hypercalcaemia spinal cord compression
and the need for bone surgery. This was a retrospective anal-
ysis not included in the original protocol.
Results
Patient characteristics
Patient demographic and baseline clinical characteristics
were almost identically matched between treatment groups
(Table 1). The median patient age was 52.8 years and 52.7
years for the oral clodronate and placebo groups, respectively.
Approximately 50% of the women in each treatment group
were postmenopausal, and the majority of women (66% in the
oral clodronate and 67% in the placebo groups) had stage II/
III disease. The treatment groups were well balanced in terms
of axillary lymph node involvement, hormone receptor status
and adjuvant endocrine and chemotherapy (Table 1).
Effect of clodronate and development of bone 
metastases and survival
The addition of oral clodronate to adjuvant therapy for breast
cancer significantly reduced the risk of bone metastases by
31% over the 5 year study period (51 patients versus 73
patients receiving placebo, HR = 0.692; P = 0.043; Figure 1
and Table 2). During the 2-year treatment period patients in
the clodronate arm had a 45% reduction in the risk of bone
metastases (P = 0.031; Table 2). Over the 5 year study period
only 6% of patients with stage I disease developed bone
Table 3
Skeletal-related events in patients developing bone 
metastases during the five year study period
Clodronate Placebo
Total number of 
patients
530 539
Skeletal-related 
event
Confirmed bone 
metastases
51 (9.6%) % of bone 73 (13.5%) % of 
bone
Radiation therapy 24 (4.5%) (48%) 47 (8.7%) (69%)
Non-vertebral 
fracture
6 (1.1%) (2%) 16 (2.9%) (22%)
Vertebral fracture 6 (1.1%) (2%) 14 (2.6%) (19%)
Hypercalcemia 3 (0.5%) (1%) 11 (2.0%) (15%)
Spinal cord 
compression
2 (0.4%) (1%) 5 (0.9%) (7%)
Bone surgery 1 (0.2%) (1%) 4 (0.7%) (5%)
Overall for 5 year 
study period1 (any 
skeletal event)
29 (5.5%) (0.4%) 53 (9.8%) (73%)
1P < 0.01 versus placebo.
Figure 2
Hazard ratios and 95% confidence intervals (CI) for the incidence of bone metastases in patient subgroups
bone metastases in patient subgroups.
Figure 3
Incidence of bone metastases in stage II/III patients. HR, hazard ratio.
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metastases compared with 15% of patients with stage II dis-
ease and 34% of patients with stage III disease.
As shown in Figure 2 and Table 2, hazard ratios for bone
metastases confirmed a similar risk reduction for bone metas-
tases for all patient subgroups that received oral clodronate,
apart from patients with relatively low risk stage I disease,
where the numbers of events were too small to provide any
meaningful comparison. For stage II/III disease, over the 5 year
study period, the clodronate treated patients had a 41%
decrease in the risk of developing bone metastases (P =
0.009); during the 2 year medication period, the risk was
decreased by 50% (P = 0.020; Figure 3).
For the 51 of 530 clodronate patients and the 73 of 539 pla-
cebo patients who developed bone metastases, there was evi-
dence of a reduction in the number of bone metastases-
related bone events in clodronate patients (29/530; 5.5%)
compared with placebo patients (53/539; 9.8%) (P < 0.01;
Table 3). This shows that, although there were only 51 of the
clodronate patients who relapsed in bone compared to 73 of
the placebo patients, they did not do worse because of previ-
ous adjuvant clodronate. In fact, only 57% of these patients
developed skeletal events compared to 73% of the bone
relapsed placebo patients. This indicates that previous clodr-
onate therapy does not appear to have compromised the sub-
sequent treatment of relapsed metastatic bone disease.
With regard to non-osseous metastases arising during the 5
year study period, there was no significant difference in the
occurrence of visceral metastases for patients randomized to
clodronate: 79 patients versus 94 placebo patients (HR =
0.84, 95% CI 0.62–1.13; P = 0.24). For patients with stage
II/III disease, there was a similar non-significant reduction in
visceral metastases for women randomized to clodronate: 64
patients versus 81 placebo patients (HR = 0.77, 95% CI
0.56–1.07; P = 0.12; Table 2).
Patients who received oral clodronate had an overall survival
advantage as reported previously [18], although this is no
longer statistically significant due to multiple analyses. This
was observed for all patients (Figure 4) and for patients with
stage II/III disease (Figure 5). There was a 23% reduction in
the risk of death in all patients (HR = 0.768, 95% CI 0.591–
0.999; P = 0.048) and a 26% reduction in risk of death in the
subset of patients with stage II/III disease (HR = 0.743, 95%
CI 0.558–0.989; P = 0.041), although neither of these
reached statistical significance because of multiple analyses.
Safety and tolerability
Overall, there were no reports of drug-related serious adverse
events. Study medication was stopped early due to adverse
events in 13% of patients receiving oral clodronate compared
with 11% of patients receiving placebo.
Although the most frequently reported adverse events were
gastrointestinal (Table 4), diarrhoea was the only adverse
event to demonstrate a statistically significant increase in inci-
dence in the clodronate treatment group. Diarrhoea occurred
in 19.9% of the clodronate-treated patients versus 10% of the
placebo-treated patients (P < 0.05) and was generally mild.
There were no cases of oesophageal perforation or ulceration
or osteonecrosis of the mandible and/or maxilla, which have
been associated with the use of other bisphosphonates [20].
Table 4
Incidence of gastrointestinal adverse events occurring in t 10% 
of patients during the two year treatment period
Percentage of patients with event
Clodronate (n = 
530)
Placebo (n = 539)
Nausea 27.0 29.8
Diarrhoea1 19.9 10.0
Dyspepsia 15.6 13.3
Vomiting 14.7 13.1
Abdominal pain 13.6 10.5
Constipation 12.5 12.2
Stomatitis 8.4 10.2
1P < 0.05 versus placebo.
Figure 4
Overall survival in all patients. HR, hazard ratio.
Figure 5
Overall survival in stage II/III patients. HR, hazard ratio.
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Discussion
The addition of oral clodronate 1,600 mg daily for 2 years to
standard adjuvant therapy significantly reduced the overall risk
of bone metastases in patients with primary operable breast
cancer during the first 5 years after primary diagnosis. The
impact of oral clodronate therapy on bone metastasis was
most pronounced during the 2 year treatment period but per-
sisted throughout the 5 year study period.
Though not part of the original analysis plan, we examined the
incidence of skeletal-related events in the patients who devel-
oped bone metastases. Treatment for these patients was at
the discretion of the investigator. However, it was general
practice to use a bisphosphonate when bone metastases
occurred. Consistently, the data show fewer metastatic bone
events in the patients who previously received adjuvant clodr-
onate, supporting the benefit of adjuvant use rather than wait-
ing until the bone metastases have occurred (Table 3).
Furthermore, in this trial adjuvant clodronate did not show any
evidence of a detrimental effect on visceral metastases and
overall survival was significantly improved, clearly demonstrat-
ing that early treatment has clinical benefit.
The findings from this study confirm those of an earlier report
of a small, randomized, open-label study with oral clodronate
involving 302 women with newly diagnosed primary breast
cancer, who also had micrometastases detected in the bone
marrow [7,17]. These patients were randomly assigned to
receive oral clodronate 1,600 mg/day or not during a 2 year
treatment period. All patients received standard adjuvant ther-
apies, including surgery, radiotherapy, endocrine therapy, and/
or chemotherapy. The two arms were well balanced with
respect to prognostic factors during the 3 year follow-up
period. Patients who received oral clodronate had an approxi-
mately 50% reduction in the incidence of bone metastases
(8% versus 17% with placebo; P = 0.003), and a significantly
longer bone metastasis-free survival (P < 0.001) compared to
those receiving standard treatment.
Another small, randomized, open-label study of similar size (N
= 299) was published indicating no reduction in the incidence
of skeletal metastases in the clodronate arm [21]. The investi-
gators also claimed a negative effect of oral clodronate on vis-
ceral metastasis-free and overall survival, particularly in
oestrogen receptor-negative breast cancer patients. There
was, however, a significant imbalance in the treatment arms in
this small, unblinded study, with respect to the important prog-
nostic factors of oestrogen receptor status with significantly
more oestrogen receptor-negative patients assigned to oral
clodronate treatment (25 patients randomly assigned to clodr-
onate treatment versus 10 patients to the control group; P =
0.03). Furthermore, these oestrogen receptor-negative
patients were treated with endocrine therapy, rather than the
established standard of chemotherapy for such patients [21].
Their reported significant reduction in survival was lost when
this imbalance in oestrogen receptor negativity was corrected.
In contrast, our study reported here was a large, double blind,
placebo-controlled trial. Randomization resulted in two treat-
ment arms that were evenly balanced for all prognostic factors,
including oestrogen receptor. Thus, the significant reduction
in bone metastases and the trend towards improvement in
overall survival observed in the clodronate arm in our trial we
believe can be attributed to treatment with clodronate.
In the present study, oral clodronate was generally well toler-
ated. This safety profile is supported by over 260,000 patient
years of marketing experience in 67 countries with clodronate
used for treatment of hypercalcaemia and metastatic bone dis-
ease.
Conclusion
The data from this trial indicate that the addition of oral clodr-
onate, 1,600 mg daily for 2 years to standard adjuvant breast
cancer therapy can significantly reduce the occurrence of
bone metastases over a 5 year period. This benefit, together
with the very low toxicity and substantial safety of clodronate,
supports its use as additional adjuvant therapy for patients
with primary breast cancer, particularly those at high risk of
metastatic relapse. Questions such as the optional duration of
therapy and efficacy in stage I disease remain to be answered.
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